April 13, 2026 |
Discover how teams from across Inizio provided a range of integrated services to give a client’s product the best chance of launch success.

Discover how teams from across Inizio provided a range of integrated services to give a client’s product the best chance of launch success – including market analysis, sales teams, MSLs, training, launch meeting support, congress experiences, and product value demonstration.
Our client is a US biotechnology company that specializes in developing therapies for complex and chronic conditions. For many years, the firm has been working on what’s become the first new FDA-approved therapy of its kind in almost two decades.
Our client’s landmark product is an easy-to-use therapy that allows for rapid absorption and targets various receptors. In clinical trials, the treatment was shown to significantly reduce pain.
Primarily, the client needed a commercialization partner to rapidly set up a large, flexible nationwide sales team ready for the product launch in October 2025.
Read the full case study here.
This content was provided by Inizio
Latest Content from Inizio
Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding
Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers,…
Pegasus, the UK’s leading independent health communications consultancy, added three awards to its 2014 portfolio at last weekend’s AMEC International Summit 2014 in Amsterdam
Brighton consultancy adds top honour to its award wins
Brighton-based independent healthcare specialist looks to add award to growing list of accolades
Top UK Healthcare Communications Consultancy Moves to Brighton
A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation…
Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.
How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from…
Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards…
